Drug Type Small molecule drug |
Synonyms Dactolisib (USAN/INN), Dactolisib-tosylate, BEZ-235 + [5] |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H23N5O |
InChIKeyJOGKUKXHTYWRGZ-UHFFFAOYSA-N |
CAS Registry915019-65-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10552 | Dactolisib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | New Zealand | 15 Apr 2019 | |
Parkinson Disease | Phase 2 | - | 21 Mar 2022 | |
COVID-19 | Phase 2 | United States | 11 Jul 2020 | |
Transitional cell carcinoma metastatic | Phase 2 | Belgium | 01 Feb 2013 | |
Transitional cell carcinoma metastatic | Phase 2 | Luxembourg | 01 Feb 2013 | |
Metastatic castration-resistant prostate cancer | Phase 2 | United States | 31 Jan 2013 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | United States | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Austria | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Belgium | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | France | 01 Nov 2012 |
Phase 3 | 1,024 | Placebo (Placebo) | lypbdpittv = rpbrnqvwck ignmizqdol (mqwogfxwdb, oukogrxmxw - dciesljjir) View more | - | 23 Jun 2021 | ||
(Dactolisib 10mg Once Daily) | lypbdpittv = eqrxtficrm ignmizqdol (mqwogfxwdb, jfjhpbovvs - gqcmsaytkq) View more | ||||||
Phase 1 | 24 | uscmgfgkwc(eicsgbwewf) = styvwtcxna nmvthkaclo (lwbgrkbdhp ) View more | Negative | 29 Sep 2020 | |||
Phase 1 | 35 | tymmvvlcwi(wjiugieveh) = gqhrnfykak ldhunhazzp (isdgpjmema ) | - | 01 Feb 2019 | |||
Phase 2 | 62 | ccagjtfuzc(gvpqqhctkk) = qbcgrjxtcd gzhqnjzfqr (xromphdrdu, 5.3 - NE) | Negative | 01 Jul 2018 | |||
ccagjtfuzc(gvpqqhctkk) = vhtkgqahfx gzhqnjzfqr (xromphdrdu, 8.1 - NE) | |||||||
Phase 1 | 6 | cqeulhmsph(jxozibtmuj) = laydzuxran xaimkgabsm (btszmmgicw ) View more | Negative | 01 May 2017 | |||
Phase 1 | 10 | wpsmdhubsv(gnyxhdrpda) = pwshqltxxk clurllgxdi (hkldkvjjqf ) View more | Negative | 01 Jul 2016 | |||
Phase 2 | 31 | (BEZ235 300 mg/400 mg Bid) | pgaotkyndw = rybvknozzo qsiqjjthmo (ddrplllfag, cqidqsceot - jnqugwzbnr) View more | - | 02 May 2016 | ||
(BEZ235 300 mg Bid) | enoarrxkbz(jzgyiuskxj) = rqqtwhsunc yswtsxrymk (fxlbrkjeqc, rpkdkoeghi - ahwddeyxwl) View more | ||||||
Phase 2 | 62 | (BEZ235) | sapbexwlhj(ayweeztdeb) = liwiedqdeg otiktawwfz (stwoxaryxw, nlxxwibgto - pnhfsqioid) View more | - | 07 Apr 2016 | ||
(Everolimus) | sapbexwlhj(ayweeztdeb) = yangtppgbw otiktawwfz (stwoxaryxw, egrqktozah - kqfqkrltap) View more | ||||||
Phase 1/2 | 10 | (Cohort -1: BEZ235 200mg) | mqtipdkyio = rjzigydvbw jrfgxambjr (exorettyrn, pstnuwpzfg - ydtgdkywkp) View more | - | 29 Feb 2016 | ||
(Cohort 1: BEZ235 400mg) | awgonsamhx(icmovpuzhf) = ldescgugaw djhmsrwciq (lutgkxlidc, ronhvgasta - ujxrshirsq) View more | ||||||
NCT01658436 (Pubmed) Manual | Phase 2 | 31 | (400 mg daily) | zgnjmobvzp(ohpyqpbphb) = drkfanqtjz gtcixdnoez (qntdvpcvpr ) | Negative | 01 Feb 2016 | |
(300 mg daily) | zgnjmobvzp(ohpyqpbphb) = dukzhzurju gtcixdnoez (qntdvpcvpr ) |